223 related articles for article (PubMed ID: 34383201)
1. Hypoxic Hepatocellular Carcinoma Cells Acquire Arsenic Trioxide Resistance by Upregulating HIF-1α Expression.
Chen Y; Li H; Chen D; Jiang X; Wang W; Li D; Shan H
Dig Dis Sci; 2022 Aug; 67(8):3806-3816. PubMed ID: 34383201
[TBL] [Abstract][Full Text] [Related]
2. Periostin contributes to arsenic trioxide resistance in hepatocellular carcinoma cells under hypoxia.
Liu Y; Gao F; Song W
Biomed Pharmacother; 2017 Apr; 88():342-348. PubMed ID: 28119236
[TBL] [Abstract][Full Text] [Related]
3. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
[TBL] [Abstract][Full Text] [Related]
4. Arsenic trioxide inhibits angiogenesis of hepatocellular carcinoma after insufficient radiofrequency ablation via blocking paracrine angiopoietin-1 and angiopoietin-2.
Dong S; Li Z; Kong J; Wu S; Gao J; Sun W
Int J Hyperthermia; 2022; 39(1):888-896. PubMed ID: 35848416
[TBL] [Abstract][Full Text] [Related]
5. An Akt/hypoxia-inducible factor-1alpha/platelet-derived growth factor-BB autocrine loop mediates hypoxia-induced chemoresistance in liver cancer cells and tumorigenic hepatic progenitor cells.
Lau CK; Yang ZF; Ho DW; Ng MN; Yeoh GC; Poon RT; Fan ST
Clin Cancer Res; 2009 May; 15(10):3462-71. PubMed ID: 19447872
[TBL] [Abstract][Full Text] [Related]
6. Sirolimus increases the anti-cancer effect of Huai Er by regulating hypoxia inducible factor-1α-mediated glycolysis in hepatocellular carcinoma.
Zhou L; Zhao Y; Pan LC; Wang J; Shi XJ; Du GS; He Q
World J Gastroenterol; 2022 Aug; 28(32):4600-4619. PubMed ID: 36157928
[TBL] [Abstract][Full Text] [Related]
7. Long non-coding RNA PAARH promotes hepatocellular carcinoma progression and angiogenesis via upregulating HOTTIP and activating HIF-1α/VEGF signaling.
Wei H; Xu Z; Chen L; Wei Q; Huang Z; Liu G; Li W; Wang J; Tang Q; Pu J
Cell Death Dis; 2022 Feb; 13(2):102. PubMed ID: 35110549
[TBL] [Abstract][Full Text] [Related]
8. The epigallocatechin gallate derivative Y
Liao ZH; Zhu HQ; Chen YY; Chen RL; Fu LX; Li L; Zhou H; Zhou JL; Liang G
J Ethnopharmacol; 2020 Sep; 259():112852. PubMed ID: 32278759
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib inhibits hypoxia-inducible factor-1α synthesis: implications for antiangiogenic activity in hepatocellular carcinoma.
Liu LP; Ho RL; Chen GG; Lai PB
Clin Cancer Res; 2012 Oct; 18(20):5662-71. PubMed ID: 22929805
[TBL] [Abstract][Full Text] [Related]
10. Antisense hypoxia-inducible factor 1alpha gene therapy enhances the therapeutic efficacy of doxorubicin to combat hepatocellular carcinoma.
Liu F; Wang P; Jiang X; Tan G; Qiao H; Jiang H; Krissansen GW; Sun X
Cancer Sci; 2008 Oct; 99(10):2055-61. PubMed ID: 19016766
[TBL] [Abstract][Full Text] [Related]
11. γ-H2AX promotes hepatocellular carcinoma angiogenesis via EGFR/HIF-1α/VEGF pathways under hypoxic condition.
Xiao H; Tong R; Ding C; Lv Z; Du C; Peng C; Cheng S; Xie H; Zhou L; Wu J; Zheng S
Oncotarget; 2015 Feb; 6(4):2180-92. PubMed ID: 25537504
[TBL] [Abstract][Full Text] [Related]
12. The hypoxia-inducible factor 1 inhibitor LW6 mediates the HIF-1α/PD-L1 axis and suppresses tumor growth of hepatocellular carcinoma in vitro and in vivo.
Xu H; Chen Y; Li Z; Zhang H; Liu J; Han J
Eur J Pharmacol; 2022 Sep; 930():175154. PubMed ID: 35868447
[TBL] [Abstract][Full Text] [Related]
13. Arsenic Sulfide Inhibits Hepatocellular Carcinoma Metastasis by Suppressing the HIF-1α/VEGF Pathway.
Lu S; Cai Y; Kang T; Zhu C; Feng Z; Chen S
Front Biosci (Landmark Ed); 2023 Jul; 28(7):152. PubMed ID: 37525902
[TBL] [Abstract][Full Text] [Related]
14. Expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in hepatocellular carcinoma: Impact on neovascularization and survival.
Huang GW; Yang LY; Lu WQ
World J Gastroenterol; 2005 Mar; 11(11):1705-8. PubMed ID: 15786555
[TBL] [Abstract][Full Text] [Related]
15. HIF-1α promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment.
Wang M; Zhao X; Zhu D; Liu T; Liang X; Liu F; Zhang Y; Dong X; Sun B
J Exp Clin Cancer Res; 2017 Apr; 36(1):60. PubMed ID: 28449718
[TBL] [Abstract][Full Text] [Related]
16. ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization in vivo.
Moser C; Lang SA; Mori A; Hellerbrand C; Schlitt HJ; Geissler EK; Fogler WE; Stoeltzing O
BMC Cancer; 2008 Jul; 8():206. PubMed ID: 18651980
[TBL] [Abstract][Full Text] [Related]
17. BMP9-ID1 Signaling Activates HIF-1α and VEGFA Expression to Promote Tumor Angiogenesis in Hepatocellular Carcinoma.
Chen H; Nio K; Tang H; Yamashita T; Okada H; Li Y; Doan PTB; Li R; Lv J; Sakai Y; Yamashita T; Mizukoshi E; Honda M; Kaneko S
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163396
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia-induced TRPM7 promotes glycolytic metabolism and progression in hepatocellular carcinoma.
Zhao F; Yu W; Hu J; Xia Y; Li Y; Liu S; Liu A; Wang C; Zhang H; Zhang L; Shi J
Eur J Pharmacol; 2024 Jul; 974():176601. PubMed ID: 38677534
[TBL] [Abstract][Full Text] [Related]
19. Effects of hypoxia-inducible factor-1α silencing on the proliferation of CBRH-7919 hepatoma cells.
Xu LF; Ni JY; Sun HL; Chen YT; Wu YD
World J Gastroenterol; 2013 Mar; 19(11):1749-59. PubMed ID: 23555163
[TBL] [Abstract][Full Text] [Related]
20. HIPK2 suppresses tumor growth and progression of hepatocellular carcinoma through promoting the degradation of HIF-1α.
Chen P; Duan X; Li X; Li J; Ba Q; Wang H
Oncogene; 2020 Apr; 39(14):2863-2876. PubMed ID: 32034309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
